CD19/CD20/BCMA CAR-T / Shanghai Cell Therapy Group - LARVOL DELTA

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL) (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Shanghai Cell Therapy Group Co.,Ltd | Active, not recruiting ➔ Recruiting | Trial completion date: Jul 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2026

Enrollment open • Trial completion date • Trial primary completion date • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CXCL8 • IL15 • IL4

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Shanghai Cell Therapy Group Co.,Ltd

CAR T-Cell Therapy • New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology